RayzeBio, Inc.
RYZBDelisted Feb 26, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001825367
RayzeBio, Inc. was delisted on Feb 26, 2024; its insiders filed their last Form 4 on Feb 28, 2024; 107 institutions reported holding it in 13F filings for Q4 2023, worth $3.40B in total; superinvestors Viking Global Investors and HHLR Advisors (Hillhouse) held it.
13F holders, Q4 2023
Institutional positions in RayzeBio, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
RYZB is no longer listed, so this page shows Q4 2023. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 107
- +39 vs. Q3 2023
- Shares held
- 54.8M
- +577.6K (+1.1%) vs. Q3 2023
- Total value
- $3.40B
- +$2.20B (+183.2%) vs. Q3 2023
- New holders
- 59
- 19 more added
- Sold out
- 20
- 18 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RYZB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 107 | $3.40B |
| Q3 2023 | 68 | $1.20B |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding RayzeBio, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 2,365,213 | $147.0M | 2.95% | −257,696−9.8% | Reduced |
| Sofinnova Investments, Inc. | 2,419,528 | $150.4M | 8.43% | 00.0% | Unchanged |
| Wellington Management Group LLP | 3,504,409 | $215.9M | 0.04% | −371,777−9.6% | Reduced |
| VR Adviser, LLC | 4,030,471 | $250.6M | 17.19% | +13,624+0.3% | Added |
| Versant Venture Management, LLC | 5,158,161 | $320.7M | 82.47% | 00.0% | Unchanged |
| venBio Partners LLC | 5,158,162 | $320.7M | 48.06% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 6,642,700 | $413.0M | 1.51% | 00.0% | Unchanged |
| Artal Group S.A. | 0 | $0 | 0.00% | −555,556−100.0% | Sold out |
| Avidity Partners Management LP | 0 | $0 | 0.00% | −500,000−100.0% | Sold out |
| Braidwell LP | 0 | $0 | 0.00% | −277,778−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −213,757−100.0% | Sold out |
| Hood River Capital Management LLC | 0 | $0 | 0.00% | −84,111−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −77,459−100.0% | Sold out |
| TD Asset Management Inc | 0 | $0 | 0.00% | −72,610−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −59,835−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −54,009−100.0% | Sold out |
| Discovery Capital Management, LLC | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Greenland Capital Management LP | 0 | $0 | 0.00% | −48,737−100.0% | Sold out |
| RTW Investments, LP | 0 | $0 | 0.00% | −46,300−100.0% | Sold out |
| Point72 Middle East FZE | 0 | $0 | 0.00% | −45,275−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −38,500−100.0% | Sold out |
| Monashee Investment Management LLC | 0 | $0 | 0.00% | −27,500−100.0% | Sold out |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Soros Fund Management LLCSuperinvestorSoros Fund Management | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −16,653−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −14,847−100.0% | Sold out |
| Norges Bank | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |